2026 Q1 -tulosraportti
66 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
3,63%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 t sittenWith the prescription figures that have come since Q1 sales of the Wegovy pill at 2,256 Mia DKK. How can Danske Bank's full-year expectations only be adjusted from 12 to 14 mia DKK. I expect - at a minimum - a Q2 revenue of5 mia DKK. In addition, there will be launches in new markets for the rest of the year. Shouldn't the expectation rather be 20 mia DKK?
I believe it is realistic and will confirm that the pill can be one of the most important growth drivers in the long term.
·5 t sittenIs it not in August that the upcoming dividend payment is decided or paid out? Should we expect approx 8 kr or do you think that the fall in revenue will affect the size of the dividend? They surely don't pay dividends to the small 4.4 million shares they have bought back?!
The dividend last year in August was 3.75. Don't know what it will be this year, but it's around that. (the 8 kr are in the spring)
·7 t sittenNew stock exchange announcement Saturday 11.juli-2026: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916579 Plainsboro, NJ and Bagsværd, Denmark, July 11, 2026 – Novo Nordisk today unveiled new data from the phase 3 FRONTIER4 extension study evaluating the long-term safety and efficacy of investigational denecimig (Mim8) subcutaneous prophylaxis in children, adolescents, and adults with hemophilia A, with or without inhibitors, across a range of dosing frequencies including once-monthly, once-every-two-weeks, and once-weekly administration. These results and other data across Novo Nordisk’s hemophilia portfolio were presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Paris. “The positive safety and efficacy findings from FRONTIER4 reinforce denecimig’s potential as a preventive treatment option for children, adolescents, and adults with hemophilia A, regardless of their inhibitor status or the dosing frequency used,” said Dr. Martin Holst Lange, chief scientific officer and executive vice president, Research & Development at Novo Nordisk. “The breadth and totality of our data presented at ISTH reflect Novo Nordisk’s commitment to advancing treatment innovation to address the diverse needs of people living with hemophilia.” Interim analyses from the open-label, phase 3 FRONTIER4 long-term safety and efficacy study included 426 people with hemophilia A aged 1 year and older on denecimig prophylaxis (365 adults and adolescents with a median observation period of 0.50 years; 61 children with a median observation period of 0.33 years). For the primary study endpoint of safety, denecimig was found to be consistent with findings previously shared from the FRONTIER research program. Injection-site reactions (ISR) were reported at low rates in children (2.0% of injections) and in adolescents and adults (1.8% of injections), and all were mild and transient. No clinical evidence of neutralizing antibodies was observed. For the secondary study endpoints of efficacy, estimated mean annualized bleeding rates (ABRs) were consistent with findings from the FRONTIER research program across all dosing regimens and regardless of inhibitor status (ABRs: 0.75; 95% CI 0.60, 0.93 for adults and adolescents; 0.37; 95% CI 0.17, 0.76 for children). Across all doses, approximately 71% of adults and adolescents and 89% of children experienced zero treated bleeds while receiving denecimig.1,2 The interim assessment of exploratory patient-reported outcomes (PROs) from the long-term FRONTIER4 study showed findings from prior FRONTIER trials were maintained long-term in all dosing frequencies studied, including improved joint pain for people aged 12 and older (Joint Pain Rating Scale, JPRS) and reduced treatment burden for those aged one and older (Hemophilia Treatment Experience Measure, Hemo-TEM). Across all age groups and dosing frequencies, 94.1% of 185 participants found the denecimig pen-injector easy or very easy to use, and 89.7% found it quick or very quick to prepare and inject (Hemophilia Device Assessment Tool, HDAT).4 New post hoc analyses of participants aged 12 and older with available thrombin generation data from the phase 3 FRONTIER2 and FRONTIER5 studies found that denecimig prophylaxis increased thrombin generation, a measure of the body’s ability to form clots, into the normal reference range in adolescents and adults without excessive response. These findings further support denecimig’s data across the clinical program.5 In September 2025, Novo Nordisk submitted denecimig for review to the US Food and Drug Administration (FDA) through a Biologics License Application (BLA). “When managing a chronic condition like hemophilia A, it's important that treatments are evaluated over the long-term and also offer dosing optionality,” said Guy Young, MD, Director, Hemostasis and Thrombosis Center at Children's Hospital, Los Angeles. “These data suggest denecimig, which has delivered consistent results across the entire FRONTIER program, has the potential to have a truly meaningful impact for a diverse array of people with hemophilia A.” In addition to the latest denecimig data, Novo Nordisk is also presenting first-time results from the phase 3 open-label concizumab explorer10 trial evaluating the efficacy and safety of concizumab prophylaxis in 24 children below the age of 12 living with hemophilia A or B with inhibitors. In the trial, the estimated mean ABR on concizumab prophylaxis was 2.08 (95% CI 1.27, 3.41) compared to 11.51 (95% CI 7.75, 17.09) for previous on-demand treatment and the ABR ratio was 0.18 (95% CI 0.11, 0.29), representing an 82% reduction in ABR with concizumab compared to prior on-demand treatment. Eighty-three percent of the participants reported at least one on-treatment adverse event. Most events were mild in severity (152 out of 192 events) and with reported outcome as recovered (178 out of 192 events).
- 20 t sittenUPDATE: July 11, 2026 The launch of Eli Lilly’s Foundayo remains “muted,” with weekly prescriptions flat over the last five weeks, analysts from Jefferies said in a July 10 note. The analysis is based on data collected by IQVIA. In the 13th week of Foundayo’s launch, IQVIA reported 19,550 prescriptions, down for the third straight week after peaking at Week 10 with 21,648 prescriptions. The figure also comes in significantly shy of the Week 13 launch of Novo’s Wegovy pill (more than 105K scripts) and Lilly’s injected obesity treatment Zepbound (59K), but ahead of Novo’s injected Wegovy (13K). Meanwhile, weekly scripts for Wegovy pill ticked slightly upward sequentially to about 153K, although they still lag behind the drug’s peak of more than 161K. Jefferies points out that CVS was the last of the big three PBMs to provide coverage of Foundayo, starting on June 1. By contrast, Wegovy had full coverage at the first week of its launch. While Jefferies’ $71 million quarterly sales projection for Foundayo sits significantly below Wall Street consensus of $130 million, the team still believes that the Lilly med can reach the consensus revenue estimate of $1.2 billion for 2026.I don't understand the picture. Did Novo Nordisk start alone in the market for oral GLP-1. Novo started early January 20026, while Eli Lilly started early April 2926.
·1 päivä sitten · MuokattuNovo price after hours 323.57
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
66 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
3,63%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenWith the prescription figures that have come since Q1 sales of the Wegovy pill at 2,256 Mia DKK. How can Danske Bank's full-year expectations only be adjusted from 12 to 14 mia DKK. I expect - at a minimum - a Q2 revenue of5 mia DKK. In addition, there will be launches in new markets for the rest of the year. Shouldn't the expectation rather be 20 mia DKK?I believe it is realistic and will confirm that the pill can be one of the most important growth drivers in the long term.
- ·5 t sittenIs it not in August that the upcoming dividend payment is decided or paid out? Should we expect approx 8 kr or do you think that the fall in revenue will affect the size of the dividend? They surely don't pay dividends to the small 4.4 million shares they have bought back?!The dividend last year in August was 3.75. Don't know what it will be this year, but it's around that. (the 8 kr are in the spring)
- ·7 t sittenNew stock exchange announcement Saturday 11.juli-2026: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916579 Plainsboro, NJ and Bagsværd, Denmark, July 11, 2026 – Novo Nordisk today unveiled new data from the phase 3 FRONTIER4 extension study evaluating the long-term safety and efficacy of investigational denecimig (Mim8) subcutaneous prophylaxis in children, adolescents, and adults with hemophilia A, with or without inhibitors, across a range of dosing frequencies including once-monthly, once-every-two-weeks, and once-weekly administration. These results and other data across Novo Nordisk’s hemophilia portfolio were presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Paris. “The positive safety and efficacy findings from FRONTIER4 reinforce denecimig’s potential as a preventive treatment option for children, adolescents, and adults with hemophilia A, regardless of their inhibitor status or the dosing frequency used,” said Dr. Martin Holst Lange, chief scientific officer and executive vice president, Research & Development at Novo Nordisk. “The breadth and totality of our data presented at ISTH reflect Novo Nordisk’s commitment to advancing treatment innovation to address the diverse needs of people living with hemophilia.” Interim analyses from the open-label, phase 3 FRONTIER4 long-term safety and efficacy study included 426 people with hemophilia A aged 1 year and older on denecimig prophylaxis (365 adults and adolescents with a median observation period of 0.50 years; 61 children with a median observation period of 0.33 years). For the primary study endpoint of safety, denecimig was found to be consistent with findings previously shared from the FRONTIER research program. Injection-site reactions (ISR) were reported at low rates in children (2.0% of injections) and in adolescents and adults (1.8% of injections), and all were mild and transient. No clinical evidence of neutralizing antibodies was observed. For the secondary study endpoints of efficacy, estimated mean annualized bleeding rates (ABRs) were consistent with findings from the FRONTIER research program across all dosing regimens and regardless of inhibitor status (ABRs: 0.75; 95% CI 0.60, 0.93 for adults and adolescents; 0.37; 95% CI 0.17, 0.76 for children). Across all doses, approximately 71% of adults and adolescents and 89% of children experienced zero treated bleeds while receiving denecimig.1,2 The interim assessment of exploratory patient-reported outcomes (PROs) from the long-term FRONTIER4 study showed findings from prior FRONTIER trials were maintained long-term in all dosing frequencies studied, including improved joint pain for people aged 12 and older (Joint Pain Rating Scale, JPRS) and reduced treatment burden for those aged one and older (Hemophilia Treatment Experience Measure, Hemo-TEM). Across all age groups and dosing frequencies, 94.1% of 185 participants found the denecimig pen-injector easy or very easy to use, and 89.7% found it quick or very quick to prepare and inject (Hemophilia Device Assessment Tool, HDAT).4 New post hoc analyses of participants aged 12 and older with available thrombin generation data from the phase 3 FRONTIER2 and FRONTIER5 studies found that denecimig prophylaxis increased thrombin generation, a measure of the body’s ability to form clots, into the normal reference range in adolescents and adults without excessive response. These findings further support denecimig’s data across the clinical program.5 In September 2025, Novo Nordisk submitted denecimig for review to the US Food and Drug Administration (FDA) through a Biologics License Application (BLA). “When managing a chronic condition like hemophilia A, it's important that treatments are evaluated over the long-term and also offer dosing optionality,” said Guy Young, MD, Director, Hemostasis and Thrombosis Center at Children's Hospital, Los Angeles. “These data suggest denecimig, which has delivered consistent results across the entire FRONTIER program, has the potential to have a truly meaningful impact for a diverse array of people with hemophilia A.” In addition to the latest denecimig data, Novo Nordisk is also presenting first-time results from the phase 3 open-label concizumab explorer10 trial evaluating the efficacy and safety of concizumab prophylaxis in 24 children below the age of 12 living with hemophilia A or B with inhibitors. In the trial, the estimated mean ABR on concizumab prophylaxis was 2.08 (95% CI 1.27, 3.41) compared to 11.51 (95% CI 7.75, 17.09) for previous on-demand treatment and the ABR ratio was 0.18 (95% CI 0.11, 0.29), representing an 82% reduction in ABR with concizumab compared to prior on-demand treatment. Eighty-three percent of the participants reported at least one on-treatment adverse event. Most events were mild in severity (152 out of 192 events) and with reported outcome as recovered (178 out of 192 events).
- 20 t sittenUPDATE: July 11, 2026 The launch of Eli Lilly’s Foundayo remains “muted,” with weekly prescriptions flat over the last five weeks, analysts from Jefferies said in a July 10 note. The analysis is based on data collected by IQVIA. In the 13th week of Foundayo’s launch, IQVIA reported 19,550 prescriptions, down for the third straight week after peaking at Week 10 with 21,648 prescriptions. The figure also comes in significantly shy of the Week 13 launch of Novo’s Wegovy pill (more than 105K scripts) and Lilly’s injected obesity treatment Zepbound (59K), but ahead of Novo’s injected Wegovy (13K). Meanwhile, weekly scripts for Wegovy pill ticked slightly upward sequentially to about 153K, although they still lag behind the drug’s peak of more than 161K. Jefferies points out that CVS was the last of the big three PBMs to provide coverage of Foundayo, starting on June 1. By contrast, Wegovy had full coverage at the first week of its launch. While Jefferies’ $71 million quarterly sales projection for Foundayo sits significantly below Wall Street consensus of $130 million, the team still believes that the Lilly med can reach the consensus revenue estimate of $1.2 billion for 2026.I don't understand the picture. Did Novo Nordisk start alone in the market for oral GLP-1. Novo started early January 20026, while Eli Lilly started early April 2926.
- ·1 päivä sitten · MuokattuNovo price after hours 323.57
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
2026 Q1 -tulosraportti
66 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
7,95 DKK/osake
Viimeisin osinko
3,63%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenWith the prescription figures that have come since Q1 sales of the Wegovy pill at 2,256 Mia DKK. How can Danske Bank's full-year expectations only be adjusted from 12 to 14 mia DKK. I expect - at a minimum - a Q2 revenue of5 mia DKK. In addition, there will be launches in new markets for the rest of the year. Shouldn't the expectation rather be 20 mia DKK?I believe it is realistic and will confirm that the pill can be one of the most important growth drivers in the long term.
- ·5 t sittenIs it not in August that the upcoming dividend payment is decided or paid out? Should we expect approx 8 kr or do you think that the fall in revenue will affect the size of the dividend? They surely don't pay dividends to the small 4.4 million shares they have bought back?!The dividend last year in August was 3.75. Don't know what it will be this year, but it's around that. (the 8 kr are in the spring)
- ·7 t sittenNew stock exchange announcement Saturday 11.juli-2026: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916579 Plainsboro, NJ and Bagsværd, Denmark, July 11, 2026 – Novo Nordisk today unveiled new data from the phase 3 FRONTIER4 extension study evaluating the long-term safety and efficacy of investigational denecimig (Mim8) subcutaneous prophylaxis in children, adolescents, and adults with hemophilia A, with or without inhibitors, across a range of dosing frequencies including once-monthly, once-every-two-weeks, and once-weekly administration. These results and other data across Novo Nordisk’s hemophilia portfolio were presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Paris. “The positive safety and efficacy findings from FRONTIER4 reinforce denecimig’s potential as a preventive treatment option for children, adolescents, and adults with hemophilia A, regardless of their inhibitor status or the dosing frequency used,” said Dr. Martin Holst Lange, chief scientific officer and executive vice president, Research & Development at Novo Nordisk. “The breadth and totality of our data presented at ISTH reflect Novo Nordisk’s commitment to advancing treatment innovation to address the diverse needs of people living with hemophilia.” Interim analyses from the open-label, phase 3 FRONTIER4 long-term safety and efficacy study included 426 people with hemophilia A aged 1 year and older on denecimig prophylaxis (365 adults and adolescents with a median observation period of 0.50 years; 61 children with a median observation period of 0.33 years). For the primary study endpoint of safety, denecimig was found to be consistent with findings previously shared from the FRONTIER research program. Injection-site reactions (ISR) were reported at low rates in children (2.0% of injections) and in adolescents and adults (1.8% of injections), and all were mild and transient. No clinical evidence of neutralizing antibodies was observed. For the secondary study endpoints of efficacy, estimated mean annualized bleeding rates (ABRs) were consistent with findings from the FRONTIER research program across all dosing regimens and regardless of inhibitor status (ABRs: 0.75; 95% CI 0.60, 0.93 for adults and adolescents; 0.37; 95% CI 0.17, 0.76 for children). Across all doses, approximately 71% of adults and adolescents and 89% of children experienced zero treated bleeds while receiving denecimig.1,2 The interim assessment of exploratory patient-reported outcomes (PROs) from the long-term FRONTIER4 study showed findings from prior FRONTIER trials were maintained long-term in all dosing frequencies studied, including improved joint pain for people aged 12 and older (Joint Pain Rating Scale, JPRS) and reduced treatment burden for those aged one and older (Hemophilia Treatment Experience Measure, Hemo-TEM). Across all age groups and dosing frequencies, 94.1% of 185 participants found the denecimig pen-injector easy or very easy to use, and 89.7% found it quick or very quick to prepare and inject (Hemophilia Device Assessment Tool, HDAT).4 New post hoc analyses of participants aged 12 and older with available thrombin generation data from the phase 3 FRONTIER2 and FRONTIER5 studies found that denecimig prophylaxis increased thrombin generation, a measure of the body’s ability to form clots, into the normal reference range in adolescents and adults without excessive response. These findings further support denecimig’s data across the clinical program.5 In September 2025, Novo Nordisk submitted denecimig for review to the US Food and Drug Administration (FDA) through a Biologics License Application (BLA). “When managing a chronic condition like hemophilia A, it's important that treatments are evaluated over the long-term and also offer dosing optionality,” said Guy Young, MD, Director, Hemostasis and Thrombosis Center at Children's Hospital, Los Angeles. “These data suggest denecimig, which has delivered consistent results across the entire FRONTIER program, has the potential to have a truly meaningful impact for a diverse array of people with hemophilia A.” In addition to the latest denecimig data, Novo Nordisk is also presenting first-time results from the phase 3 open-label concizumab explorer10 trial evaluating the efficacy and safety of concizumab prophylaxis in 24 children below the age of 12 living with hemophilia A or B with inhibitors. In the trial, the estimated mean ABR on concizumab prophylaxis was 2.08 (95% CI 1.27, 3.41) compared to 11.51 (95% CI 7.75, 17.09) for previous on-demand treatment and the ABR ratio was 0.18 (95% CI 0.11, 0.29), representing an 82% reduction in ABR with concizumab compared to prior on-demand treatment. Eighty-three percent of the participants reported at least one on-treatment adverse event. Most events were mild in severity (152 out of 192 events) and with reported outcome as recovered (178 out of 192 events).
- 20 t sittenUPDATE: July 11, 2026 The launch of Eli Lilly’s Foundayo remains “muted,” with weekly prescriptions flat over the last five weeks, analysts from Jefferies said in a July 10 note. The analysis is based on data collected by IQVIA. In the 13th week of Foundayo’s launch, IQVIA reported 19,550 prescriptions, down for the third straight week after peaking at Week 10 with 21,648 prescriptions. The figure also comes in significantly shy of the Week 13 launch of Novo’s Wegovy pill (more than 105K scripts) and Lilly’s injected obesity treatment Zepbound (59K), but ahead of Novo’s injected Wegovy (13K). Meanwhile, weekly scripts for Wegovy pill ticked slightly upward sequentially to about 153K, although they still lag behind the drug’s peak of more than 161K. Jefferies points out that CVS was the last of the big three PBMs to provide coverage of Foundayo, starting on June 1. By contrast, Wegovy had full coverage at the first week of its launch. While Jefferies’ $71 million quarterly sales projection for Foundayo sits significantly below Wall Street consensus of $130 million, the team still believes that the Lilly med can reach the consensus revenue estimate of $1.2 billion for 2026.I don't understand the picture. Did Novo Nordisk start alone in the market for oral GLP-1. Novo started early January 20026, while Eli Lilly started early April 2926.
- ·1 päivä sitten · MuokattuNovo price after hours 323.57
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt